Metabolomics-based study of potential biomarkers of sepsis

Abstract

The purpose of our study was to explore potential characteristic biomarkers in patients with sepsis. Peripheral blood specimens from sepsis patients and normal human volunteers were processed by liquid chromatography-mass spectrometry-based analysis. Outlier data were excluded by principal component analysis and orthogonal partial least squares-discriminant analysis using the metabolomics R software package metaX and MetaboAnalyst 5.0 (https://www.metaboanalyst.ca/home.xhtml) online analysis software, and differential metabolite counts were identified by using volcano and heatmaps. The obtained differential metabolites were combined with KEGG (Kyoto Gene and Kyoto Encyclopedia) analysis to screen out potential core differential metabolites, and ROC curves were drawn to analyze the changes in serum metabolites in sepsis patients and to explore the potential value of the metabolites in the diagnosis of sepsis patients. By metabolomic analysis, nine differential metabolites were screened for their significance in guiding the diagnosis and differential diagnosis of sepsis namely: 3-phenyl lactic acid, N-phenylacetylglutamine, phenylethylamine, traumatin, xanthine, methyl jasmonate, indole, l-tryptophan and 1107116. In this study, nine metabolites were finally screened based on metabolomic analysis and used as potential characteristic biomarkers for the diagnosis of sepsis.

Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality

“…The functional activity of IDO1 was also suggested by the positive correlation of phenylalanine pathway metabolites with HPD , FAH , and SLC16A1 in PBMC transcriptomics, which are genes associated with the active conversion of phenylpyruvate from phenylalanine ( 69 – 71 ) ( Supplemental Figure 3F ). Furthermore, phenylalanine, tyrosine, and tryptophan metabolism has been previously reported to be dysregulated in patients with sepsis, suggesting this dysregulation may be elicited in response to multiple types of severe infections ( 72 ). These observations indicate that these metabolites could be evaluated clinically in early COVID-19 to assess disease severity, and intervention via modulation of nutrients may prove beneficial, with several clinical trials currently underway in patients with COVID-19 to evaluate amino acid supplementation ( 73 – 75 ).…”

Role of the Gut Bacteria-Derived Metabolite Phenylacetylglutamine in Health and Diseases

“…Metabolomic analysis in patients with sepsis and healthy volunteers shows elevated n -phenylacetylglutamine levels in sepsis patients indicating its biomarker potential in diagnosing sepsis . PAGln appears to have a protective effect in rheumatoid arthritis .…”

Effects of Long-term Microgravity Exposure on Liver Activity and the Gut Microbiota as well as Gut-liver Axis Homeostasis

“…Among these microbially derived metabolites, N-phenylacetylglutamine, which impairs the ring rate and induces axonal damage in cultured neurons[28], is highly expressed in the sepsis group [29] and is elevated in concentrations associated with phenylketonuria [30]. In addition, conjugated secondary bile acids (BAs), glycoursodeoxycholic acid (glyco-UDCA) and glycolithocholic acid (glyo-LCA) are reduced along with the microbial genera Lactobacillus (Firmicutes) and Prevotella (Bacteroidetes), in which deconjugated UDCA is oxidized and epimerized of bile acids by Actinobacteria, Proteobacteria, Firmicutes and Bacteroidetes [31], and LCA is involved in dihydroxylation of bile acids by Firmicutes (Clostridium and Extibacter spp.)…”